TherapeuticsMD Past Earnings Performance

Past criteria checks 0/6

TherapeuticsMD has been growing earnings at an average annual rate of 58.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 22.2% per year.

Key information

58.2%

Earnings growth rate

63.7%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate-22.2%
Return on equity-14.6%
Net Margin-248.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How TherapeuticsMD makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:29TA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242-450
30 Jun 241-560
31 Mar 241-670
31 Dec 231-890
30 Sep 236942180
30 Jun 237029300
31 Mar 237017420
31 Dec 22701570
30 Sep 22-643-26-6
30 Jun 22-39-3010-4
31 Mar 22-17-5848-2
31 Dec 213-79730
30 Sep 2191-1721948
30 Jun 2185-1571828
31 Mar 2172-1661789
31 Dec 2065-18419310
30 Sep 2058-19119812
30 Jun 2063-19020415
31 Mar 2058-19319617
31 Dec 1950-17617520
30 Sep 1939-16615722
30 Jun 1919-17014225
31 Mar 1916-14813027
31 Dec 1816-13311627
30 Sep 1815-1159532
30 Jun 1816-947631
31 Mar 1817-806233
31 Dec 1717-775834
30 Sep 1717-786033
30 Jun 1718-896341
31 Mar 1718-905947
31 Dec 1619-905154
30 Sep 1620-854457
30 Jun 1620-793659
31 Mar 1621-853269
31 Dec 1520-852972
30 Sep 1519-842673
30 Jun 1518-822571
31 Mar 1517-662355
31 Dec 1415-542243
30 Sep 1414-462135
30 Jun 1412-362024
31 Mar 1410-312018
31 Dec 139-281914

Quality Earnings: 29TA is currently unprofitable.

Growing Profit Margin: 29TA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 29TA is unprofitable, but has reduced losses over the past 5 years at a rate of 58.2% per year.

Accelerating Growth: Unable to compare 29TA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 29TA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: 29TA has a negative Return on Equity (-14.64%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 15:43
End of Day Share Price 2024/12/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TherapeuticsMD, Inc. is covered by 18 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John TannerCantor Fitzgerald & Co.
Robert LabickCJS Securities, Inc.
Esther RajaveluDeutsche Bank